71 results
8-K
9h7zp
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
DEFA14A
yi3f4mas
21 Mar 22
Additional proxy soliciting materials
4:05pm
8-K
6l8s7oxdh
21 Mar 22
Other Events
4:05pm
8-K
EX-99.2
p21lucrdu9p3ryw 18
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
58hvw5cr8rkq m3
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
ddtou43bzsdlg8l
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.2
fff3zub6wgj8pn0
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
qt890a
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
leglqrl62aadvz12
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am